Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma Retraction in /10.3892/ol.2024.14847

Zhang,Zhen‑Hai; Wu,Ya‑Guang; Qin,Cheng‑Kun; Rong,Zhong‑Hou; Su,Zhong‑Xue; Xian,Guo‑Zhe

doi:10.3892/ol.2014.2520

Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma

Retraction in 10.3892/ol.2024.14847

Authors:
- Zhen‑Hai Zhang
- Ya‑Guang Wu
- Cheng‑Kun Qin
- Zhong‑Hou Rong
- Zhong‑Xue Su
- Guo‑Zhe Xian
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: September 10, 2014 https://doi.org/10.3892/ol.2014.2520
Pages: 2160-2164

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have shown that the expression level of stanniocalcin 2 (STC2) is associated with tumor progression. However, to date, the association between STC2 and clinicopathological factors in hepatocellular carcinoma (HCC) has not been investigated. The clinical significance of STC2 was investigated in 30 fresh HCC samples using western blot analysis and in 240 HCC tissues using immunohistochemical analysis. The level of STC2 in cancerous tissue was higher than in the matched non‑cancerous tissues. Using immunohistochemistry, the STC2‑positive group exhibited a higher incidence of lymph node metastasis and venous invasion compared with the STC2‑negative group. Kaplan‑Meier survival analysis revealed that the positive expression of STC2 correlated with poor overall survival (OS) and disease‑free survival of HCC patients (P<0.01). STC2 expression was observed to be an independent prognostic factor for OS in HCC patients by multivariate analysis (hazard ratio, 2.39; 95% confidence interval, 1.04‑5.89; P=0.013). These data suggest that STC2 expression may be a useful indicator of poor prognosis in HCC patients.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
2	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012.
3	Sherman M: Recurrence of hepatocellular carcinoma. N Engl J Med. 359:2045–2047. 2008.
4	Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 31:339–346. 2002.
5	Tsai CL, Koong AC, Hsu FM, et al: Biomarker studies on radiotherapy to hepatocellular carcinoma. Oncology. 84:64–68. 2013.
6	Jellinek DA, Chang AC, Larsen MR, et al: Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochem J. 350:453–461. 2000.
7	Yeung BH, Law AY and Wong CK: Evolution and roles of stanniocalcin. Mol Cell Endocrinol. 349:272–280. 2012.
8	Meyer HA, Tölle A, Jung M, et al: Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol. 55:669–678. 2009.
9	Esseghir S, Kennedy A, Seedhar P, et al: Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Cancer Res. 13:3164–3173. 2007.
10	Almeida M, Muñoz J, Nunes S and Fonseca-Moutinho J: Cyclooxygenase-2 immunoexpression in breast cancer: progesterone receptor influence. Cancer Epidemiol. 35:e81–e84. 2011.
11	Tazi el M, Essadi I, M’rabti H, Touyar A and Errihani PH: Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N Am J Med Sci. 3:167–175. 2011.
12	Qu L, Wang Y, Gong L, et al: Suicide gene therapy for hepatocellular carcinoma cells by survivin promoter-driven expression of the herpes simplex virus thymidine kinase gene. Oncol Rep. 29:1435–1440. 2013.
13	Tada F, Abe M, Hirooka M, et al: Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol. 41:1601–1609. 2012.
14	Xie B, Zhou J, Yuan L, et al: Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol. 44:795–801. 2013.
15	Ieta K, Tanaka F, Yokobori T, et al: Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer. 125:926–931. 2009.
16	Yokobori T, Mimori K, Ishii H, et al: Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann Surg Oncol. 17:2601–2607. 2010.
17	Tamura K, Furihata M, Chung SY, et al: Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci. 100:914–919. 2009.
18	Volland S, Kugler W, Schweigerer L, Wilting J and Becker J: Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. Int J Cancer. 125:2049–2057. 2009.
19	Bouras T, Southey MC, Chang AC, et al: Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res. 62:1289–1295. 2002.
20	Esseghir S, Kennedy A, Seedhar P, et al: Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Cancer Res. 13:3164–3173. 2007.
21	Arigami T, Uenosono Y, Ishigami S, Yanagita S, Hagihara T, Haraguchi N, Matsushita D, Hirahara T, et al: Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer. Oncol Rep. 30:2838–2844. 2013.
22	Ito D, Walker JR, Thompson CS, et al: Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol. 24:9456–9469. 2004.
23	Law AY and Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res. 316:466–476. 2010.
24	Joensuu K, Heikkilä P and Andersson LC: Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett. 265:76–83. 2008.
25	Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D, Sandaltzopoulos R, Liotta LA, Gimotty PA and Coukos G: Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol. 25:852–861. 2007.